<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02625636</url>
  </required_header>
  <id_info>
    <org_study_id>TDU14518</org_study_id>
    <secondary_id>U1111-1172-1152</secondary_id>
    <nct_id>NCT02625636</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Doses of SAR438544 in Comparison to Placebo and Glucagon in Healthy Subjects and Type 1 Diabetes Mellitus Patients</brief_title>
  <official_title>A Randomized, Double-blind, Glucagon and Placebo-controlled Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Single Escalating Doses of SAR438544 Administered by Subcutaneous Route in Healthy Subjects and Patients With Type 1diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      To assess the tolerability and safety of SAR438544 after single ascending subcutaneous (SC)&#xD;
      doses in healthy subjects and in type 1 diabetes mellitus (T1DM) patients.&#xD;
&#xD;
      Secondary Objective:&#xD;
&#xD;
      To assess the preliminary pharmacodynamics (PD) and pharmacokinetic (PK) parameters of&#xD;
      SAR438544 after single ascending SC doses in healthy subjects and in T1DM patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthy subjects:&#xD;
&#xD;
      The total duration of study per subject is up to 4.5 weeks with 2 to 21 days screening&#xD;
      period, 1 day for treatment, and 7 days (+/- 1 day) follow-up after IMP administration.&#xD;
&#xD;
      T1DM patients:&#xD;
&#xD;
      The total duration of study per patient is up to 5.5 weeks with 3 to 28 days screening&#xD;
      period, 1 day for treatment, and 7 days (+/- 1 day) follow-up after IMP administration.&#xD;
&#xD;
      One or more interim analyses may be performed to support decisions for the next steps of the&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>Day 1 to Day 7 (+/- 1 day)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of PD parameter: continuous monitoring of blood glucose levels over a period of 6 hours post-dose</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PD parameter: area under plasma concentration of the BG-time curve between investigational medicinal product (IMP) dosing and time t (BG-AUC0-t)</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PD parameter: BG-maximum concentration (BG-Cmax)</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PD parameter: BG-time to Cmax (BG-tmax)</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter (recombinant glucagon and SAR438544): Cmax</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter (recombinant glucagon and SAR438544): tmax</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter (recombinant glucagon and SAR438544): tlast</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter (recombinant glucagon and SAR438544): terminal half life</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter (recombinant glucagon and SAR438544): area under curve from zero time until the last measurable concentration (AUClast)</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter (recombinant glucagon and SAR438544): AUC</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter (recombinant glucagon and SAR438544): partial AUCs (AUC0-t)</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>SAR438544 dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of SAR438544 given SC under fasting conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAR438544 dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of SAR438544 given SC under fasting conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAR438544 dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of SAR438544 given SC under fasting conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose of placebo given SC under fasting conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucagon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose of glucagon given SC under fasting conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAR438544 Optional Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Optional lower, intermediate, or higher dose of SAR438544 given SC under fasting conditions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAR438544</intervention_name>
    <description>Pharmaceutical form: solution&#xD;
Route of administration: subcutaneous</description>
    <arm_group_label>SAR438544 Optional Dose</arm_group_label>
    <arm_group_label>SAR438544 dose 1</arm_group_label>
    <arm_group_label>SAR438544 dose 2</arm_group_label>
    <arm_group_label>SAR438544 dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Pharmaceutical form: solution&#xD;
Route of administration: subcutaneous</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>r-glucagon</intervention_name>
    <description>Pharmaceutical form: solution&#xD;
Route of administration: subcutaneous</description>
    <arm_group_label>Glucagon</arm_group_label>
    <other_name>GlucaGenÂ® HypoKit, glucagon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :&#xD;
&#xD;
        Healthy subjects:&#xD;
&#xD;
          -  Male or female subjects, between 18 and 45 years of age, inclusive.&#xD;
&#xD;
          -  Body weight between 50.0 and 100.0 kg, inclusive, if male, and between 40.0 and 90.0&#xD;
             kg, inclusive, if female, body mass index (BMI) between 18.0 and 30.0 kg/m^2,&#xD;
             inclusive.&#xD;
&#xD;
          -  Certified as healthy by a comprehensive clinical assessment (detailed medical history&#xD;
             and complete physical examination).&#xD;
&#xD;
          -  Female subject must use a double contraception method, including a highly effective&#xD;
             method of birth control, except if she has undergone sterilization defined as tubal&#xD;
             occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy, and&#xD;
             bilateral tubal ligation at least 3 months earlier or is postmenopausal.&#xD;
&#xD;
          -  The accepted double contraception methods include the use of intrauterine device or&#xD;
             hormonal contraception started at least 30 days prior to the screening start and&#xD;
             continued for at least 3 months after IMP dosing in addition to one of the following&#xD;
             contraceptive options: (1) condom plus spermicide; (2) diaphragm plus spermicide or&#xD;
             cervical/vault cap plus spermicide. Menopause is defined as being amenorrheic for at&#xD;
             least 2 years with plasma FSH level &gt;30 UI/L in women older than 40 years of age&#xD;
&#xD;
          -  Having given written informed consent prior to undertaking any study-related&#xD;
             procedure.&#xD;
&#xD;
          -  Not under any administrative or legal supervision.&#xD;
&#xD;
          -  Male subject, whose partners are of childbearing potential (including lactating&#xD;
             women), must accept to use, during sexual intercourse, a double contraception method&#xD;
             according to the following algorithm: (condom, diaphragm or cervical cap, plus&#xD;
             spermicide) plus (intra-uterine device or hormonal contraceptive) from the inclusion&#xD;
             up to 3 months after the last dosing (except if sterilized).&#xD;
&#xD;
          -  Male subject, whose partners are pregnant, must use, during sexual intercourse, a&#xD;
             condom from the inclusion up to 3 months after the last dosing.&#xD;
&#xD;
          -  Male subject has agreed not to donate sperm from the inclusion up to 3 months after&#xD;
             the last dosing.&#xD;
&#xD;
        T1DM patients:&#xD;
&#xD;
          -  Male or female patients, between 18 and 60 years of age, inclusive, with T1DM for at&#xD;
             least one year, as defined by the American Diabetes Association.&#xD;
&#xD;
          -  Total (basal+short acting) daily insulin dose of &lt;1.2 U/kg/day.&#xD;
&#xD;
          -  Body weight between 50.0 and 110 kg, inclusive, the BMI between 18.5 and 30.0 kg/m^2,&#xD;
             inclusive.&#xD;
&#xD;
          -  Fasting serum C-peptide &lt;0.3 nmol/L.&#xD;
&#xD;
          -  Glycohemoglobin (HbA1c) â¤75 mmol/mol (â¤9%).&#xD;
&#xD;
          -  Stable insulin regimen for at least 2 months prior to study and self-monitoring of&#xD;
             blood glucose before screening visit.&#xD;
&#xD;
          -  Certified as otherwise healthy for T1DM by assessment of medical history and physical&#xD;
             examination (cardiovascular system, chest and lungs, thyroid, abdomen, nervous system,&#xD;
             skin and mucosae, and musculoskeletal system), unless the Investigator considers any&#xD;
             abnormality to be clinically irrelevant and not interfering with the conduct of the&#xD;
             study.&#xD;
&#xD;
          -  Female subject must use a double contraception method, including a highly effective&#xD;
             method of birth control, except if she has undergone sterilization defined as tubal&#xD;
             occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy, and&#xD;
             bilateral tubal ligation at least 3 months earlier or is postmenopausal.&#xD;
&#xD;
          -  The accepted double contraception methods include the use of intrauterine device or&#xD;
             hormonal contraception started at least 30 days prior to the screening start and&#xD;
             continued for at least 3 months after IMP dosing in addition to one of the following&#xD;
             contraceptive options: (1) condom plus spermicide; (2) diaphragm plus spermicide or&#xD;
             cervical/vault cap plus spermicide. Menopause is defined as being amenorrheic for at&#xD;
             least 2 years with plasma FSH level &gt;30 UI/L in women older than 40 years of age.&#xD;
&#xD;
          -  Having given written informed consent prior to undertaking any study-related&#xD;
             procedure.&#xD;
&#xD;
          -  Not under any administrative or legal supervision.&#xD;
&#xD;
          -  Male subject, whose partners are of childbearing potential (including lactating&#xD;
             women), must accept to use, during sexual intercourse, a double contraception method&#xD;
             according to the following algorithm: (condom, diaphragm or cervical cap, plus&#xD;
             spermicide) plus (intra-uterine device or hormonal contraceptive) from the inclusion&#xD;
             up to 3 months after the last dosing (except if sterilized).&#xD;
&#xD;
          -  Male subject, whose partners are pregnant, must use, during sexual intercourse, a&#xD;
             condom from the inclusion up to 3 months after the last dosing.&#xD;
&#xD;
          -  Male subject has agreed not to donate sperm from the inclusion up to 3 months after&#xD;
             the last dosing.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        Healthy subjects:&#xD;
&#xD;
          -  Any history or presence of clinically relevant cardiovascular, pulmonary,&#xD;
             gastrointestinal, hepatic, renal, metabolic, hematological, neurological,&#xD;
             osteomuscular, articular, psychiatric, systemic, ocular, gynecologic (if female), or&#xD;
             infectious disease, or signs of acute illness.&#xD;
&#xD;
          -  Frequent headaches and/or migraine, recurrent nausea and/or vomiting (more than twice&#xD;
             a month).&#xD;
&#xD;
          -  Blood donation, any volume, within 2 months before inclusion.&#xD;
&#xD;
          -  Symptomatic postural hypotension, irrespective of the decrease in blood pressure, or&#xD;
             asymptomatic postural hypotension defined as a decrease in systolic blood pressure â¥20&#xD;
             mmHg within 3 minutes when changing from supine to standing position.&#xD;
&#xD;
          -  Presence or history of any drug allergy or allergic disease that in the opinion of the&#xD;
             Investigator may interfere with subject safety or data integrity during the study.&#xD;
&#xD;
          -  History or presence of drug or alcohol abuse (alcohol consumption more than 40 g per&#xD;
             day on a regular basis).&#xD;
&#xD;
          -  Smoking more than 5 cigarettes or equivalent per day, unable to stop smoking during&#xD;
             the study.&#xD;
&#xD;
          -  If female, pregnancy (defined as positive beta-human chorionic gonadotropin [Î²-HCG]&#xD;
             blood test), breast-feeding.&#xD;
&#xD;
          -  Any medication (including St John's Wort) within 14 days before inclusion or within 5&#xD;
             times the elimination half-life or PD half-life of the medication, with the exception&#xD;
             of hormonal contraception or menopausal hormone replacement therapy; any vaccination&#xD;
             within the last 28 days and any biologics (antibody or its derivatives) given within 4&#xD;
             months before inclusion.&#xD;
&#xD;
          -  Any subject who, in the judgment of the Investigator, is likely to be noncompliant&#xD;
             during the study, or unable to cooperate because of a language problem or poor mental&#xD;
             development.&#xD;
&#xD;
          -  Positive result on any of the following tests: hepatitis B surface (HBs Ag) antigen,&#xD;
             anti-hepatitis C virus (anti-HCV) antibodies, anti-human immunodeficiency virus 1 and&#xD;
             2 antibodies (anti-HIV1 and anti HIV2 Ab) and human immunodeficiency virus 1 antigen&#xD;
             (HIV1 Ag).&#xD;
&#xD;
          -  Positive result on urine drug screen (amphetamines/methamphetamines, barbiturates,&#xD;
             benzodiazepines, cannabinoids, cocaine, opiates).&#xD;
&#xD;
          -  Positive alcohol breath test.&#xD;
&#xD;
        T1DM patients:&#xD;
&#xD;
          -  Any history or presence of clinically relevant cardiovascular (includes ischemia,&#xD;
             atrioventricular [AV] block; arrhythmias), pulmonary, gastrointestinal, hepatic,&#xD;
             renal, metabolic (apart from diabetes mellitus type 1), hematological, neurological,&#xD;
             osteomuscular, articular, psychiatric, systemic, ocular, gynecologic (if female), or&#xD;
             infectious disease, or signs of acute illness.&#xD;
&#xD;
          -  Severe hypoglycemia resulting in coma/seizures or requiring assistance of another&#xD;
             person, and/or hospitalization for diabetic ketoacidosis in the last 6 months before&#xD;
             screening visit.&#xD;
&#xD;
          -  Frequent severe headaches and/or migraine, recurrent nausea and/or vomiting (more than&#xD;
             twice a month).&#xD;
&#xD;
          -  Blood loss (&gt;300 mL) within 3 months before inclusion.&#xD;
&#xD;
          -  Symptomatic postural hypotension, irrespective of the decrease in blood pressure, or&#xD;
             asymptomatic postural hypotension defined as a decrease in systolic blood pressure â¥20&#xD;
             mmHg within 3 minutes when changing from supine to standing position.&#xD;
&#xD;
          -  Presence or history of any drug allergy or allergic disease that in the opinion of the&#xD;
             Investigator may interfere with patient safety or data integrity during the study.&#xD;
&#xD;
          -  Likelihood of requiring treatment during the study period with drugs not permitted by&#xD;
             the clinical study protocol.&#xD;
&#xD;
          -  If female, pregnancy (defined as positive Î²-HCG blood test), breast-feeding at&#xD;
             screening and before any treatment periods (defined as positive Î²-HCG urine test).&#xD;
&#xD;
          -  Any patient who, in the judgment of the Investigator, is likely to be noncompliant&#xD;
             during the study, or unable to cooperate because of a language problem or poor mental&#xD;
             development.&#xD;
&#xD;
          -  Positive result on any of the following tests: HBs Ag, anti-HCV Abs, anti-HIV1 and&#xD;
             anti-HIV2 Abs and HIV1 Ag.&#xD;
&#xD;
          -  Positive result on urine drug screen (amphetamines/methamphetamines, barbiturates,&#xD;
             benzodiazepines, cannabinoids, cocaine, opiates).&#xD;
&#xD;
          -  Positive alcohol breath test.&#xD;
&#xD;
          -  Known hypersensitivity to glucagon, lactose or any other constituent in GlucaGen^Â®&#xD;
             HypoKit and SAR438544 and their excipients.&#xD;
&#xD;
          -  Any contraindication from the use of glucagon:&#xD;
&#xD;
          -  Pheochromocytoma&#xD;
&#xD;
          -  Insulinoma and glucagonoma&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 840001</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>December 7, 2015</study_first_submitted>
  <study_first_submitted_qc>December 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2015</study_first_posted>
  <last_update_submitted>August 22, 2016</last_update_submitted>
  <last_update_submitted_qc>August 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

